Zydus Lifesciences gets EIR for Vadodara API manufacturing facility from USFDA

10 Jun 2025 Evaluate

Zydus Lifesciences has received the Establishment Inspection Report (EIR) from the USFDA for the inspection conducted at its API manufacturing facility located at Dabhasa near Vadodara. This facility underwent an inspection from April 21 to April 25 2025 and has been classified as Voluntary Action Indicated (VAI). FDA confirmed the inspection as closed.

Zydus Lifesciences (formerly known as Cadila Healthcare), a company limited by shares, incorporated and domiciled in India, operates as an integrated pharmaceutical company with business encompassing the entire value chain in the research, development, production, marketing and distribution of pharmaceutical products.

Zydus Lifesciences Share Price

931.45 -3.75 (-0.40%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×